Affirming Hormone Treatment for a Transgender Adolescent After a Venous Thromboembolic Event

Scott W Penney; Jenny H Jung; Aaron J Ballantyne; Dina S Parekh; David A Klein; Shelton A Viola

doi:10.1097/MPH.0000000000002442

Affirming Hormone Treatment for a Transgender Adolescent After a Venous Thromboembolic Event

Scott W Penney, Jenny H Jung, Aaron J Ballantyne, Dina S Parekh, David A Klein, Shelton A Viola

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

BACKGROUND: Medical affirmation, including gender-affirming hormones, is an essential component in the treatment of many transgender and gender-diverse youth. The risk of venous thromboembolism (VTE) during testosterone therapy for gender-affirming care is not fully elucidated.

OBSERVATION: The case describes a 17-year-old transgender male treated with testosterone therapy who presented with an occlusive deep vein thrombosis of right axillary and subclavian veins. Testosterone level was 920 ng/dL at the time of the deep vein thrombosis, and he had no risk factors for VTE. A complete hypercoagulable workup was negative.

CONCLUSIONS: The possibility of testosterone therapy as a risk factor for VTE may suggest the need to include this information during informed consent discussions. Long-term anticoagulation may be considered for those restarting testosterone therapy.

Original language	English
Pages (from-to)	e892-e895
Journal	Journal of Pediatric Hematology/Oncology
Volume	44
Issue number	5
DOIs	https://doi.org/10.1097/MPH.0000000000002442
State	Published - 1 Jul 2022

Keywords

Adolescent
Humans
Male
Testosterone/therapeutic use
Transgender Persons
Transsexualism
Venous Thromboembolism/drug therapy
Venous Thrombosis/drug therapy
Female

Access to Document

10.1097/MPH.0000000000002442

Cite this

@article{25bc962f5be144abaa2d27a0898b91c9,

title = "Affirming Hormone Treatment for a Transgender Adolescent After a Venous Thromboembolic Event",

abstract = "BACKGROUND: Medical affirmation, including gender-affirming hormones, is an essential component in the treatment of many transgender and gender-diverse youth. The risk of venous thromboembolism (VTE) during testosterone therapy for gender-affirming care is not fully elucidated.OBSERVATION: The case describes a 17-year-old transgender male treated with testosterone therapy who presented with an occlusive deep vein thrombosis of right axillary and subclavian veins. Testosterone level was 920 ng/dL at the time of the deep vein thrombosis, and he had no risk factors for VTE. A complete hypercoagulable workup was negative.CONCLUSIONS: The possibility of testosterone therapy as a risk factor for VTE may suggest the need to include this information during informed consent discussions. Long-term anticoagulation may be considered for those restarting testosterone therapy.",

keywords = "Adolescent, Humans, Male, Testosterone/therapeutic use, Transgender Persons, Transsexualism, Venous Thromboembolism/drug therapy, Venous Thrombosis/drug therapy, Female",

author = "Penney, {Scott W} and Jung, {Jenny H} and Ballantyne, {Aaron J} and Parekh, {Dina S} and Klein, {David A} and Viola, {Shelton A}",

year = "2022",

month = jul,

day = "1",

doi = "10.1097/MPH.0000000000002442",

language = "English",

volume = "44",

pages = "e892--e895",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Affirming Hormone Treatment for a Transgender Adolescent After a Venous Thromboembolic Event

AU - Penney, Scott W

AU - Jung, Jenny H

AU - Ballantyne, Aaron J

AU - Parekh, Dina S

AU - Klein, David A

AU - Viola, Shelton A

PY - 2022/7/1

Y1 - 2022/7/1

N2 - BACKGROUND: Medical affirmation, including gender-affirming hormones, is an essential component in the treatment of many transgender and gender-diverse youth. The risk of venous thromboembolism (VTE) during testosterone therapy for gender-affirming care is not fully elucidated.OBSERVATION: The case describes a 17-year-old transgender male treated with testosterone therapy who presented with an occlusive deep vein thrombosis of right axillary and subclavian veins. Testosterone level was 920 ng/dL at the time of the deep vein thrombosis, and he had no risk factors for VTE. A complete hypercoagulable workup was negative.CONCLUSIONS: The possibility of testosterone therapy as a risk factor for VTE may suggest the need to include this information during informed consent discussions. Long-term anticoagulation may be considered for those restarting testosterone therapy.

AB - BACKGROUND: Medical affirmation, including gender-affirming hormones, is an essential component in the treatment of many transgender and gender-diverse youth. The risk of venous thromboembolism (VTE) during testosterone therapy for gender-affirming care is not fully elucidated.OBSERVATION: The case describes a 17-year-old transgender male treated with testosterone therapy who presented with an occlusive deep vein thrombosis of right axillary and subclavian veins. Testosterone level was 920 ng/dL at the time of the deep vein thrombosis, and he had no risk factors for VTE. A complete hypercoagulable workup was negative.CONCLUSIONS: The possibility of testosterone therapy as a risk factor for VTE may suggest the need to include this information during informed consent discussions. Long-term anticoagulation may be considered for those restarting testosterone therapy.

KW - Adolescent

KW - Humans

KW - Male

KW - Testosterone/therapeutic use

KW - Transgender Persons

KW - Transsexualism

KW - Venous Thromboembolism/drug therapy

KW - Venous Thrombosis/drug therapy

KW - Female

U2 - 10.1097/MPH.0000000000002442

DO - 10.1097/MPH.0000000000002442

M3 - Article

C2 - 35293883

SN - 1077-4114

VL - 44

SP - e892-e895

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 5

ER -